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Abstract
Background: A protective role for glucocorticoid therapy in animal models of sepsis was shown many decades
ago. In human sepsis, there is new interest in glucocorticoid therapy at a physiological dose after reports of
improved response to vasopressor drugs and decreased mortality in a selected group of patients. However, other
reports have not confirmed these results. Cellular glucocorticoid resistance could explain a possible cause of that.
To evaluate this hypothesis, we evaluated the expression of glucocorticoid receptor beta, the dominant negative
isoform of glucocorticoid receptor, in peripheral mononuclear cells of septic patients and the effect of serum septic
patients over glucocorticoid receptor expression and glucocorticoid sensitivity in immune cells culture.
Methods: A prospective cohort study and an in vitro experimental study with matched controls were developed.
Nine patients with septic shock and nine healthy controls were prospectively enrolled. Mononuclear cells and
serum samples were obtained from the patients with sepsis on admission to the Intensive Care Unit and on the
day of discharge from hospital, and from healthy volunteers matched by age and sex with the patients.
Glucocorticoid receptor alpha and beta expression from patients and from immune cell lines cultured in the
presence of serum from septic patients were studied by western blot. Glucocorticoid sensitivity was studied in
control mononuclear cells cultured in the presence of serum from normal or septic patients. A statistical analysis
was performed using a Mann-Whitney test for non-parametric data and analysis of variance for multiple
comparison; P < 0.05 was considered significant.
Results: The patients’ glucocorticoid receptor beta expression was significantly higher on admission than on
discharge, whereas the alpha receptor was not significantly different. In vitro, septic serum induced increased
expression of both receptors in T and B cells in culture, with a greater effect on receptor beta than the control
serum. Septic serum induced glucocorticoid resistance in control mononuclear cells.
Conclusion: There is a transient increased expression of glucocorticoid receptor beta in mononuclear cells from
septic patients. Serum from septic patients induces cell glucocorticoid resistance in vitro. Our findings support a
possible cell glucocorticoid resistance in sepsis.
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Introduction
Sepsis is a leading cause of death in intensive care units
(ICUs) around the world [1]. In spite of new develop-
ments in critical care and sepsis therapy, the mortality
rates associated with severe sepsis and septic shock are
still over 30% in most reports [1-5].
A protective role for glucocorticoid (GC) therapy in
animal models of sepsis was shown many decades ago
[6,7], leading to a proposal as early as 1940 for the use
of GCs to treat patients with severe sepsis [8]. However
this therapeutic strategy has had several dramatic shifts
with time. The early approach of high dose GCs for sep-
sis therapy was abandoned when the potential benefits
initially reported [9-11] could not be replicated, and
higher mortality associated with secondary infections
was suggested [12,13]. A renewed interest in GC therapy
in sepsis, at what has been termed a physiological dose,
was seen after reports of improved response to vaso-
pressor drugs and decreased mortality in selected groups
of patients who had an inadequate response to adreno-
corticotropin hormone (ACTH) (defined as an increase
in total plasma cortisol <9 μg/dL) [14,15]. However, in
2008, the CORTICUS study [16] did not confirm these
results. This contradictory evidence still leaves much
uncertainty about the real benefits of GC therapy in sep-
sis [17-19]. The most accepted conclusion from earlier
studies was that positive GC effects in sepsis were seen
only in a restricted group of patients. Until recently,
these patients had been identified through a reduced
ACTH response, which has been termed adrenal insuffi-
ciency or inadequate response to stress [14]. This selec-
tion method and its role as a prognostic factor has also
been challenged [20-25]. Therefore it is possible that to
demonstrate any benefits for GC therapy in sepsis, it
will be necessary to define further to whom GC therapy
should be prescribed.
It is possible that target cells in some patients with
appropriate cortisol plasma levels do not fully respond to
GCs, being less sensitive to a given GC concentration - a
phenomenon called GC resistance [26-28]. These patients,
if they exist, would not be identified by the ACTH
response test but they could benefit from steroid therapy.
The actions of GCs are mediated by their receptor
(GR), which acts as a ligand-dependent transcription fac-
tor [29-31]. Although the GR is the product of a single
gene, several isoforms have been described [32,33]. The
most studied are GR alpha (GRa), the classical receptor
that mediates GC actions, and GR beta (GRb), which can
act as a dominant negative [34-37]. A change in the
expression of the GR isoforms with greater GRb expres-
sion has been proposed as a mechanism of GC resistance
in chronic inflammatory conditions such as rheumatoid
arthritis, ulcerative colitis and others [38-47]. Previous stu-
dies of the effect of sepsis on GR expression in humans
and endotoxin-treated rats have shown apparently contra-
dictory results in different cell types and tissues, leading
the authors to suggest a cell-specific GR modulation of
expression in sepsis [48-52]. However, some of the above
studies have evaluated only the mRNA levels of the GR,
which do not necessarily correlate with the receptor pro-
tein expression [47], while others have evaluated the GR
protein expression using antibodies that do not discrimi-
nate between GRa and GRb or by GC binding assays,
which evaluate only GRa [51].
It is known that normal mononuclear cells (lymphocytes
and monocytes) are sensitive to the actions of GCs. These
hormones can influence the T helper 1 and 2 cells balance
and modulate cytokine production, which subsequently
influences the inflammatory response in sepsis. It is there-
fore important to know if there is a change in GC receptor
expression and/or sensitivity in mononuclear cells in sepsis.
It has been demonstrated that inflammatory cytokines in
vitro can preferentially increase the expression of GRb in
lymphocytic cell lines and induce GC resistance [51]. It is
possible that proinflammatory cytokines or other factors
present in the serum of septic patients may induce a
greater expression of GRb leading to a GC-resistant state.
This response could be an appropriate feedback loop in
infectious diseases but it also might lead to an unbalanced
inflammatory response, which contributes to the morbid-
ity of sepsis.
This hypothesis must be evaluated because, at least in
theory, these patients could benefit from GC supplementa-
tion to overcome their lower cell GC sensitivity, even in
cases where an adequate basal cortisol level or adequate
ACTH response can be documented.
The aims of this study were:
1. To evaluate whether there is an overexpression of
the dominant-negative GCb in peripheral mononuclear
cells (PBMCs) of septic patients.
2. To assess whether factors present in the serum of
septic patients modulate the in vitro expression of GRs
and/or cell GC sensitivity.
Methods
Selection of patients and controls
Patients 18 years or older, admitted to the ICU of Univer-
sity of Chile Clinical Hospital (November 2004 to Decem-
ber 2005) were prospectively enrolled in this study. The
Institutional Ethics Board of the University of Chile
Clinical Hospital approved the study and informed
consent was obtained from all patients or relatives. The
inclusion criteria for this study were:
1. Persistent arterial hypotension - systolic arterial pres-
sure below 90 mmHg, mean arterial pressure <60 mmHg
or a reduction in systolic blood pressure of >40 mmHg
from baseline despite adequate volume resuscitation in the
absence of other causes of hypotension;
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2. Presence of at least one organ dysfunction as defined
by Marshall or by the definition used for the Sequential
Organ Failure Assessment score;
3. Infection focus site suspected or documented;
4. Elements of systemic inflammatory response - body
temperature >38°C or <36°C, heart rate >90 beats/min,
respiratory rate >20 breaths/min, white blood count
>12,000 μL-1, <4,000 μL-1 or >10% immature forms.
Exclusion criteria were:
1. GC supplementation prior to admission to ICU;
2. Hypothalamic-pituitary-adrenal axis dysfunction;
3. GC therapy within 6 months prior to admission to
the ICU;
4. HIV or advanced cancer disease;
5. Chronic inflammatory disease;
6. Pregnancy.
Demographic data, severity score of septic event, focus
of infection, identified microbiological agent and out-
come were consigned.
Healthy volunteers (n = 9) with no history of inflamma-
tory or autoimmune diseases, matched by age and sex
with patients, were included in the study after informed
consent was given. Exclusion criteria were the same as
for the patient group.
Hypothalamic-pituitary-adrenal axis evaluation
On ICU admission, the total cortisol serum and adrenal
reserve (Synacthen test) were evaluated for all patients.
Briefly, 250 μg of cosyntropin (Novartis, Basel, Switzerland)
was administered intravenously. Serum samples were
obtained immediately before cosyntropin administration
and 30 minutes and 60 minutes after. The samples were
stored at -80°C for cortisol level analysis. The hormone
level was quantified by a commercial kit (Immunlite
Cortisol®, Diagnostic Products Corporation, Los Angeles,
CA, USA).
Peripheral blood mononuclear cell preparation
Within 24 hours of admission, before GC supplementa-
tion, and on the third day in the ICU, 30 ml of venous
blood was obtained from control individuals and from all
patients. Another blood sample was obtained from
patients that survived the septic event on the day of hos-
pital discharge. Peripheral blood mononuclear cells were
isolated immediately by density gradient centrifugation
(Ficoll-Paque™ Plus, GE Healthcare.
Human cell lines
Human immune cell lines (CEM, Raji and K562 cells)
were cultured in Roswell Park Memorial Institute 1640
medium enriched with human septic or normal serum,
10% final concentration at 37°C in a 5% CO2 humidified
atmosphere.
Western blot
The expression of the cells’ GR isoforms was evaluated by
western blotting using specific antibodies for GRa (GR
P-20: sc1002; Santa Cruz Biotechnology Inc., Santa Cruz,
CA, USA) and GRb (PA3-514; Affinity BioReagents,
Golden, CO, USA), as described previously [47]. Briefly,
40 μg of total protein extract was loaded on 10% SDS-
PAGE gels. The resolved proteins were transferred onto
nitrocellulose membranes (30 mV, overnight at 4°C). The
membranes were blocked with 10% non-fat milk and incu-
bated at room temperature with the anti-GRa antibody
(1:200; GR (8P-20): sc-1002, Santa Cruz Biotechnology,
Inc.) or anti-GRb antibody (1:500; PA3-514 Affinity
Bioreagents, Inc., now called Thermo Scientific Pierce
Antibodies for 16 hours and 36 hours, respectively, and
for 1 hour with mouse monoclonal anti-actin (1:40,000)
antibody (Santa Cruz Biotechnology, Inc.). Secondary bioti-
nylated polyclonal antibodies against rabbit or mouse IgG
(DAKO) were used for GR and actin detection, respec-
tively. Immunoreactivity was detected by the enhanced
chemiluminescence method (Amersham Bioscience, Amer-
sham, UK). The densitometric analysis of the bands was
performed using the Scion Image beta 4.02 win software.
Glucocorticoid sensitivity assay
GC sensitivity was evaluated by measuring the dexametha-
sone inhibition of the lipopolysaccharide (LPS)-induced
TNFa released. PBMCs obtained from healthy human
volunteers were cultured in the presence of human septic
serum or human normal serum for 48 hours. During the
last 6 hours of culture, LPS 10 μg/ml (Escherichia coli
0111:B4) with or without dexamethasone (10-7 M) was
added. The supernatants were obtained and analyzed for
TNFa levels by ELISA assay (Biotrak Easy ELISA, Biotrak,
Amersham, UK).
Statistical analysis
For multiple comparisons, results were analyzed by analy-
sis of variance. For comparisons between two values, the
nonparametric Mann-Whitney test was used. A P value <
0.05 was considered significant. Data are expressed as
medians (range).
Results
Patients’ characteristics and hypothalamic-pituitary-
adrenal axis evaluation
Three men and six women with septic shock, median age
63 years old (range: 33 to 75 years) were included in this
study (Table 1). The median Acute Physiology and
Chronic Health Evaluation II score at admission was 27
(range: 18 to 35). The most common septic sources were
abdomen (55.6%) and lungs (33.3%). The microorganism
was identified in 55.6% (five) of the patients. A negative
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Gram stain was obtained in three of these and a positive
Gram stain was obtained in the remaining two. The med-
ian cortisol level at ICU admission was 26.43 μg/dL
(range: 13.4 μg/dL to 61.5 μg/dL); the median cortisol
levels 30 and 60 minutes after the administration of
cosyntropin were 34.7 μg/dL (range: 22.3 μg/dL to 61.5
μg/dL) and 35.8 μg/dL (range: 22.5 μg/dL to 61.5 μg/dL),
respectively. There was an increase in total plasma corti-
sol >9 μg/dL in 77.8% of the patients after cosyntropin
administration. Patients received GC supplementation
according to international recommendation [5] (Table 1).
Glucocorticoid receptor expression in the peripheral
blood mononuclear cells of septic patients
To evaluate whether sepsis is associated with changes in
PBMC GR isoform expression, western blotting was used
to evaluate the GRa and GRb cells in PBMCs from septic
patients on ICU admission and on the hospital discharge
day, which was considered as the control situation (free
of sepsis) for each patient.
Our results showed that all patients had significantly
increased GRb expression in PBMCs obtained at ICU
admission compared to their expression at the time of
hospital discharge (n = 5, P = 0.037), whereas the expres-
sion of GRa had not significantly changed (Figure 1).
The level of expression of both GR isoforms observed on
the first day in ICU was not significantly different by the
third day (Figure 2).
We also separately evaluated the change in GR isoform
expression between these dates for survivors and non-sur-
vivors among patients (mortality on 28th day of admis-
sion). Figure 3 shows that even though none of the values
reached a statistically significant difference, there was a
trend for an increased expression of GRa in non-survivors
at third day in comparison with the first day in UCI. This
trend was not observed in the survivors.
Effect of septic serum on glucocorticoid receptor isoform
expression in different cell lines
It is possible that cytokines or other factors present in
the serum of septic patients induce changes in the cell
expression of GR isotypes. To evaluate this hypothesis,
we cultured three different human immune cell lines
(CEM, Raji and K562) in the presence of serum from
septic patients or serum obtained from the control
group at 10% final concentration in the culture medium.
After 48 hours in culture, the GR protein expression
was analyzed by western blotting with specific antibodies
for both GR isoforms.
Figure 4 shows that septic serum induced significantly
higher expression of both GRa and b than serum from
healthy participants in CEM cells, a human T lymphoid
cell line. The increased expression was greater in GRb
than GRa. A similar but less potent effect was observed
for a human B lymphoid cell line, Raji. However, septic
serum had an inverse effect on K562 cells, a human cell
line derivate of chronic myelogenous leukemia. The
expression of both GR isoforms in K562 cells cultured in
the presence of septic serum was approximately 20% less
than in cells cultured in the presence of control serum
(Figure 4).
Effect of septic serum on glucocorticoid cell sensitivity
Finally, to assess whether septic serum not only modifies
GR isoform protein expression but also induces a change
in GC cell sensitivity, we evaluated the effect of septic
Table 1 Patients’ clinical characteristics
All Survivor Non-survivor








abdominal, n 5 (55.5%) 2 3
lung, n 3 (33.3%) 1 2
urinary, n 1 (11.1%) 1 0
Infectious agent demonstrated, n: 5 (55.6%) 3 2
gram positive, n 2 1 1
gram negative, n 3 2 1
APACHE II 27 (18 to 35) 25 (23 to 32) 27 (18 to 35)
Plasma cortisol level, μg/dL:
basal 26.43 (13.4 to 61.5) 23.7 (26.85) 29.7 (34.78)
30 minutes after Synacthen® 34.7 (22.3 to 61.5) 35.5 (39.4) 31.6 (36.75)
60 minutes after Synacthen® 35.8 (22.5 to 61.5) 38.35 (40.98) 32.1 (37.05)
Alive/dead, n 5 (55.5%) 4 (44.4%)
APACHE II, Acute Physiology and Chronic Health Evaluation II.
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serum versus control serum on a dexamethasone cell
sensitivity assay in control PBMCs in culture. These cells
were cultured in the presence of pooled human septic
serum taken from the patients on admission to ICU or
pooled serum from the controls. After 48 hours in cul-
ture, LPS or LPS plus dexamethasone was added to the
medium. Figure 5A shows that dexamethasone inhibited
the LPS-induced TNFa release by PBMC cultured in the
presence of normal serum. However, when cells were
cultured in septic serum, dexamethasone lost its inhibi-
tory effect (Figure 5B). The same experiment was also
performed using pooled human septic serum from both
surviving and non-surviving patients (data not shown),
which resulted in a complete loss of dexamethasone inhi-
bitory effect in both groups.
Discussion
The role of GC therapy in septic patients is still controver-
sial [19,53-55]. Dose, duration of treatment and selection
of patients influences the benefit of the therapy [19,54].
Insufficient adrenal GC secretion and peripheral GC resis-
tance are factors likely to influence the response of
patients to corticosteroids [26-28]. GC actions are
mediated through their cellular receptors. Because a domi-
nant negative effect of GRb was reported, a potential role
for this receptor in GC-resistant states has been proposed
[39-41,45]. Therefore our study evaluated the expression
of GRa and b in septic patients. The expression of GR can
have high inter-individual variability [52], so we chose to
evaluate the effect of sepsis on the expression of the GR
within the same individual. As it is impossible to know in
Figure 1 Western blot analysis of glucocorticoid receptor a and b isoforms of peripheral blood mononuclear cells from septic
patients. GRa and GRb cell expression were evaluated by western blotting in peripheral blood mononuclear cells from septic patients on ICU
admission (first day in the ICU) and on the day of hospital discharge, which was considered as the control situation (free of sepsis). The
quantification of the western blot analysis of (A) GRa and (B) GRb is shown. The values were normalized to b actin expression and are
expressed as percentage values of the control (GR expression on the day of hospital discharge). Data are presented as median value, 25% to
75% (box) and minimum-maximum (vertical line). (C) Representative western blot analysis of GRaGRb and b actin are shown. GR, glucocorticoid
receptor; ICU, intensive care unit.
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advance who will develop sepsis, we compared the mono-
nuclear GR expression in a septic state (admission to ICU)
with the same patient’s GR expression at discharge from
hospital (clinical recovery). This strategy also allowed us to
evaluate if the potential change in expression induced by
sepsis is transient or not. However, only the survivors
from sepsis could be studied (n = 5).
Our data showed no difference in the expression of GRa
in PBMC in sepsis (Figure 1). However it is important to
stress that we studied a limited number of septic patients
(nine) and only the survivors (five) were included for this
analysis. It is possible in a small sample like ours that a dif-
ference between groups can not be demonstrated, espe-
cially when there is high variability in inter-individual
responses. However, even with this limited number of
patients, our results showed that, in sepsis, there was a sig-
nificant transient increased expression of GRb in PBMC
(Figure 1). Ledderose et al. [52] also found an increase of
GRb mRNA expression in T cells from septic patients
compared to stimulated or non-stimulated T-cells of
healthy donors. That study also had very high inter-indivi-
dual variability with many overlapping results between
groups [19]. Our results showed that all patients had a
higher expression of GRb on the ICU admission day.
In sepsis, there is first a severe inflammatory reaction,
followed by an anti-inflammatory phase as a compensatory
response, corresponding in general to the third to fifth
days of sepsis evolution. Both stages are characterized by
different cytokines (TNFa, IL6 and IL1 for the inflamma-
tory stage, and IL10 and TGFb for the anti-inflammatory
stage), with potentially different effects on GR expression.
We therefore evaluated if there was a change in GR
expression by the third day in ICU. We showed that the
levels of expression of both GRa and GRb observed on
ICU admission day were maintained on the third day in
the ICU (Figure 2). To study further whether a change in
Figure 2 Western blot analysis of glucocorticoid receptor a and b isoforms of peripheral blood mononuclear cells from septic
patients on first and third day in the intensive care unit. The GRa and GRb cell expressions were evaluated by western blotting in peripheral
blood mononuclear cells from septic patients on the first and third day in ICU. The quantification of the western blot analysis of (A) GRa and (B) GRb
are shown. The values were normalized to b actin expression and are expressed as percentage values of the GR expression on the first day in ICU.
Data are presented as median value, 25% to 75% (box) and minimum-maximum (vertical line). ns = not statistically significant. (C) Representative
western blot analysis of GC receptors ab and b actin are shown. GR, glucocorticoid receptor; ICU, intensive care unit.
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expression of GR isoforms was associated with 28-day
mortality rate, we evaluated the changes of GR expression
between the first and third days in the individuals who
survived versus those who did not survive the septic event.
These results were not significantly different (Figure 3).
However, it may be of interest that a tendency for an
increased expression of GRa on the third day was
observed only in the non-survivor group (Figure 3).
It has previously been shown that pro-inflammatory
cytokines such as IL1 and TNFa increase the expression of
GRa and GRb in lymphocytic cell lines in vitro, with a
stronger effect on the expression of the b isoform [52]. The
serum of septic patients has high levels of proinflammatory
cytokines, as well as other factors such as GCs, which
could at least in part influence the expression of GR. To
assess whether soluble factors present in the serum of
septic patients induce changes in the cellular expression of
GR, we tested the effect of serum taken both from the
patients on admission to the ICU and from the control
group of healthy individuals, matched by age and sex to
the patients, on the expression of GRa and b in cells in
culture. Because the PBMC are primarily T lymphocytes
but also B-lymphocytes and monocytes, we evaluated the
effect of septic serum on T (CEM) and B (Raji) lymphoid
cell lines and in a myeloid cell line (K562). Our results
showed that, compared to control serum, the septic serum
induced an increased expression of both GR isoforms in T
and B lymphoid cells, with a stronger effect in the expres-
sion of GRb (Figure 4). This result is similar to the in vitro
effect of proinflammatory cytokines on GR [51] and is also
similar to the results obtained from PBMC in the same
septic patients (Figure 1), supporting a role for factors
Figure 3 Glucocorticoid receptor isoform expression on the first and third day in the intensive care unit for the survivors and non-
survivors of sepsis. GRa and b cell expression were evaluated on the first and third days in the ICU by western blotting of peripheral blood
mononuclear cells from septic patients who survived or did not survive the septic event. The quantification of the western blot analysis of (A) GRa
and (B) GRb are shown. The values were normalized to b actin expression and are expressed as percentage values of the GR expression on the first
day in the ICU. Data are presented as median value, 25% to 75% (box) and minimum-maximum (vertical line). ns = not statistically significant.
(C) Representative western blot analysis of GRa, b and b actin are shown. GR, glucocorticoid receptor; ICU, intensive care unit.
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present in serum during sepsis in the induction of GRb
expression. However, this same serum induced the con-
trary effect on K562 cells (Figure 4).
We have insufficient information to know whether these
results reflect a specific regulatory effect of GCs in differ-
ent cell types with particular roles in the immune response
or if they are secondary to an abnormal behavior of differ-
ent tumor cell lines. However, we have shown that septic
serum can regulate the expression of GR cells in culture.
Because the dominant negative effect of GRb has been
proved in vitro only when it has been overexpressed five
times or more than GRa, the increased expression of GRb
in itself does not necessarily imply a cell GC-resistant state
[34]. We went on to investigate whether septic serum is
also able to impair the cell GC sensitivity in cells in
culture. Figure 5A shows that dexamethasone significantly
inhibits the LPS-induced TNFa secretion from PBMC cul-
tured in the presence of pooled serum from control parti-
cipants. However, when these cells were cultured in the
presence of pooled septic serum, dexamethasone lost its
inhibitory effect (Figure 5B). The concentration of dexa-
methasone used in this assay is greater than the equivalent
reported free plasma cortisol levels in septic shock patients
treated with low-dose hydrocortisone therapy [56]. There-
fore, our results show that septic serum not only influ-
ences the expression of cell GR in culture, but can also
induce a GC-resistant state.
Finally, to explore further if the serum from patients
who survived the septic event had a different effect on the
expression of GR and/or GC sensitivity of cells in culture
Figure 4 Effect of human septic serum on glucocorticoid receptor isoform expression in different cell lines. CEM, Raji and K562 cell lines
were cultured in the presence of the patients’ septic serum and serum obtained from the control group at 10% final concentration in the
culture medium. After 48 h in culture, the GR protein expression was analyzed by western blotting with specific antibodies for GRa and b
isoforms. The quantification of the western blot analysis of (A) GRa and (B) GRb are shown (n = 9). The values were normalized to b actin
expression and are expressed as percentage values of the control (GR cell expression cultured in the presence of control serum). Data are
presented as median value, 25% to 75% (box) and minimum-maximum (vertical line). Representative western blot analysis of GRa, b and b actin
are shown for each cell line. CS, control serum; GR, glucocorticoid receptor; SS, septic serum.
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compared to the serum of non-survivors, we tested the
effect of the pooled serum obtained on admission to the
ICU from both groups of patients on GR expression and
on cell GC sensitivity, as described previously. Our results
showed that the serum from both survivors and non-survi-
vors induced the same effects in GR expression and in the
GC sensitivity test as the pooled serum from all septic
patients studied together (data not shown). Further studies
with higher number of patients are required to corrobo-
rate this data due to the limitations of the small sample
evaluated.
Conclusions
We found a transient increased expression of the domi-
nant negative GRb in PBMC from septic patients. We
also demonstrated that serum from septic patients influ-
ences the expression of GR transcriptional isoforms a
and b in cell lines in culture, increasing the dominant
negative GRb in T and B cell lines. Septic serum also
induced a GC-resistant state in PBMC from normal par-
ticipants in vitro. Therefore our results support the pre-
sence of a peripheral GC-resistant state in septic patients
associated with a higher expression of GRb which could
be caused, at least in part, by agents present in the serum
of septic patients. The small sample of patients and con-
trols (n = 9) included in this work means that further
study is required to corroborate our data and to evaluate
whether this peripheral GC resistance could be a factor
that influences the response to corticosteroid treatment
in septic patients.
Key messages
• GC treatment in sepsis and septic shock is still
controversial.
• A GC-resistant state associated with sepsis could be
important to define who could benefit from GC
treatment.
• This study suggests there is a transient increased
expression of GRb in mononuclear cells from septic
patients. We also showed that septic serum induces
cell GC resistance in vitro.
• Further study is necessary to evaluate if a higher
expression of GRb in septic patients correlates with a
better outcome with GC therapy.
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